Scarica l'app Stockscreener
1.265
8.99%
-0.125
Pre-mercato:
1.29
0.025
+1.98%
Precedente Chiudi:
$1.39
Aprire:
$1.42
Volume 24 ore:
5.09M
Relative Volume:
2.44
Capitalizzazione di mercato:
$259.33M
Reddito:
$12.87M
Utile/perdita netta:
$-114.34M
Rapporto P/E:
-1.4631
EPS:
-0.8646
Flusso di cassa netto:
$-79.23M
1 W Prestazione:
-28.53%
1M Prestazione:
-20.94%
6M Prestazione:
-37.38%
1 anno Prestazione:
-55.46%
Intervallo 1D:
$1.21
$1.42
Intervallo di 1 settimana:
$1.17
$1.95
Portata 52W:
$1.17
$4.32
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Nome
Taysha Gene Therapies Inc
Settore
Industria
Telefono
(214) 612-0000
Indirizzo
3000 PEGASUS PARK DRIVE, DALLAS
Confronta TSHA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
1.265 | 259.33M | 12.87M | -114.34M | -79.23M | -0.8646 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-27 | Iniziato | BMO Capital Markets | Outperform |
| 2024-04-09 | Iniziato | Piper Sandler | Overweight |
| 2023-02-01 | Downgrade | Jefferies | Buy → Hold |
| 2023-01-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | Downgrade | Goldman | Buy → Neutral |
| 2022-03-09 | Iniziato | Robert W. Baird | Outperform |
| 2022-03-01 | Iniziato | Wells Fargo | Overweight |
| 2022-02-18 | Iniziato | SMBC Nikko | Outperform |
| 2021-12-16 | Iniziato | Guggenheim | Buy |
| 2021-07-16 | Iniziato | Needham | Buy |
| 2021-06-24 | Iniziato | Truist | Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-06-09 | Iniziato | Wedbush | Outperform |
| 2021-06-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-05-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-05-11 | Ripresa | Jefferies | Buy |
| 2021-02-24 | Iniziato | William Blair | Outperform |
| 2021-01-05 | Iniziato | Oppenheimer | Outperform |
| 2020-10-19 | Iniziato | Chardan Capital Markets | Buy |
| 2020-10-19 | Iniziato | Goldman | Buy |
| 2020-10-19 | Iniziato | Jefferies | Buy |
| 2020-10-19 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Taysha Gene Therapies Inc Borsa (TSHA) Ultime notizie
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet - Benzinga
Taysha Stock Hits 52-Week Low at $1.17 Amid Challenges By Investing.com - Investing.com South Africa
Taysha Stock Hits 52-Week Low at $1.17 Amid Challenges - Investing.com India
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Acquired by Charles Schwab Investment Management Inc. - Defense World
Bank of New York Mellon Corp Acquires 111,989 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Is Taysha Gene Therapies (TSHA) the Best Short Squeeze Stock to Buy According to Analysts? - Insider Monkey
10 Best Short Squeeze Stocks to Buy According to Analysts - Insider Monkey
Analysts Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Price Target at $6.63 - Defense World
Taysha Gene Therapies’ SWOT analysis: stock’s potential in Rett syndrome treatment By Investing.com - Investing.com South Africa
Taysha Gene Therapies’ SWOT analysis: stock’s potential in Rett syndrome treatment - Investing.com Australia
Taysha Gene Therapies (TSHA) to Release Earnings on Tuesday - Defense World
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule - TipRanks
Taysha's Latest Stock Option Grants: Key Details for Institutional Investors - StockTitan
TSHA FY2025 EPS Forecast Raised by Cantor Fitzgerald - Defense World
Needham & Company LLC Reaffirms Buy Rating for Taysha Gene Therapies (NASDAQ:TSHA) - Defense World
Chardan Capital Reiterates Buy Rating for Taysha Gene Therapies (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies’ Positive Earnings Call Highlights - TipRanks
Positive Outlook for Taysha Gene Therapies: Buy Rating Backed by FDA Progress and Strong Financial Position - TipRanks
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2024 Earnings Call Transcript - MSN
Taysha Gene Therapies, Inc. (TSHA) Reports Q4 Loss, Tops Revenue Estimates - MSN
Taysha Gene Therapies Reports 2024 Financial Results - TipRanks
Positive Outlook on Taysha Gene Therapies: Promising Developments and Financial Stability - TipRanks
Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Taysha Gene Therapies reports FY24 EPS (36c) vs (96c) last year - TipRanks
Taysha Gene Therapies Inc Reports Full Year 2024 EPS of -$0.36 a - GuruFocus.com
Earnings call transcript: Taysha Gene's Q4 2024 reports narrower loss, stock dips - Investing.com
Earnings call transcript: Taysha Gene’s Q4 2024 reports narrower loss, stock dips - Investing.com India
Taysha Gene Therapies, Inc. SEC 10-K Report - TradingView
Can Taysha's Gene Therapy for Rett Syndrome Deliver? Key Safety Milestone Reached as Cash Extends to 2026 - StockTitan
Taysha Gene Therapies Inc (TSHA) Q4 2024: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Taysha Gene Therapies (TSHA) Projected to Post Earnings on Wednesday - Defense World
Taysha Gene Therapies to Release Full-Year 2024 Financial - GlobeNewswire
Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26 - The Manila Times
Gene Therapy Pioneer Taysha Readies Crucial 2024 Financial DisclosureHere's When - StockTitan
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.63 Average Price Target from Brokerages - Defense World
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Sold by SG Americas Securities LLC - Defense World
Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 1.3%Time to Buy? - MarketBeat
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Critical Analysis: Creative Medical Technology (NASDAQ:CELZ) vs. Taysha Gene Therapies (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies Inc (TSHA) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Taysha Gene Therapies Inc [TSHA] Records 50-Day SMA of $1.9835 - Knox Daily
Taysha's Strategic Move: 491K Stock Options Awarded to Secure Top Industry Talent - StockTitan
Rett Syndrome Market Growth Projections 2024-2034: - openPR
Prepare Yourself for Liftoff: Taysha Gene Therapies Inc (TSHA) - SETE News
Taysha Gene Therapies Inc Azioni (TSHA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.89%
0.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):